Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
1.
BMC Ophthalmol ; 19(1): 41, 2019 Feb 04.
Artigo em Inglês | MEDLINE | ID: mdl-30717687

RESUMO

BACKGROUND: To evaluate the safety and efficacy of using a lid hygiene brush prototype to wipe the lid margins with lid hygiene shampoo in subjects with normal meibomian glands. METHODS: Twelve eyes of 6 subjects were all evaluated just before and after wiping lid margins using 1) tap water alone, 2) Eye Shampoo, 3) Eye Brush, or 4) both products, each during a different week. The results after using both products twice daily for 1 month were also evaluated. Wiping efficacy was determined by post-wiping scores for the remaining fluorescein-stained 0.3% Tarivid ointment fully applied to eyelids and lid margins under microscopic view illuminated by blue light just after performing each of the four lid hygiene methods described above. RESULTS: No significant deterioration in ocular conditions occurred. Eyestrain, eye discharge, and dryness decreased with tap water (P = 0.020), Eye Shampoo (P = 0.036), and Eye Brush (P = 0.014), respectively. Sensations of eye discharge increased after 1 month of using both products (P = 0.042). The wiping efficacy of Eye Brush, Eye Shampoo or both was significantly greater than that of tap water alone (two-sided test, P = 0.003, 0.003, 0.002), and using both significantly increased efficacy above Eye Shampoo use alone (one-sided test, P = 0.009). CONCLUSIONS: Wiping lid margins using Eye Brush enhanced the cleansing power of Eye Shampoo. A daily healthcare routine using both products could be a safe and effective option for daily lid hygiene. TRIAL REGISTRATION: UMIN000016905 . Registration date: March 24, 2015; the study was prospectively registered.


Assuntos
Detergentes/uso terapêutico , Desinfecção/instrumentação , Oftalmopatias/prevenção & controle , Doenças Palpebrais/prevenção & controle , Higiene , Água/administração & dosagem , Adulto , Túnica Conjuntiva/patologia , Córnea/patologia , Dor Ocular/diagnóstico , Humanos , Masculino , Pessoa de Meia-Idade , Projetos Piloto , Estudos Prospectivos , Lágrimas/metabolismo
2.
J Oleo Sci ; 68(1): 67-78, 2019 Jan 01.
Artigo em Inglês | MEDLINE | ID: mdl-30542004

RESUMO

PURPOSE: To investigate the efficacy of eyelid margin cleansing with lid hygiene detergent in patients with obstructive meibomian gland dysfunction (MGD). METHODS: As a pilot study, we investigated the safety and efficacy of lid hygiene using tap water and/or lid hygiene shampoo in fourteen eyes of 7 normal subjects. All subjects were instructed to cleanse the eyelid margin with tap water and/or lid hygiene shampoo. As a main prospective clinical study, thirty-four eyes of 34 patients with obstructive MGD were enrolled. All subjects were instructed to cleanse the eyelid margin with lid hygiene shampoo at least once daily for 1 month. Ocular surface conditions were observed before and 1 month after study initiation. RESULTS: A significant exacerbating change (p < 0.05) was not detected after either method in the pilot study. In the main study, significant improvements were observed in tear break-up time (TBUT), lid margin lissamine green staining scores, vascular dilatation, and meibum status (p < 0.05). No significant improvements in corneal or conjunctival fluorescein staining scores, the mucocutaneous junction, lid margin deformation, or plugging were observed (p ≥ 0.05). Subjective improvements were observed in 27 subjects. Meibography revealed that 28 subjects had normal meibomian glands, and 6 subjects had meibomian gland atrophy. Significant improvements were observed in TBUT, vascular dilatation, and meibum status only in the group with normal meibomian glands (p < 0.05), but subjective symptoms and lid margin lissamine green staining scores improved in both groups (p < 0.05). No subjects experienced any problems throughout the study. CONCLUSION: Daily routine use of lid hygiene detergent can alleviate the symptoms of MGD regardless of meibomian gland atrophy.


Assuntos
Detergentes/uso terapêutico , Doenças Palpebrais/tratamento farmacológico , Doenças Palpebrais/prevenção & controle , Glândulas Tarsais/fisiopatologia , Higiene da Pele/métodos , Adulto , Idoso , Idoso de 80 Anos ou mais , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Projetos Piloto , Estudos Prospectivos , Vasodilatação/efeitos dos fármacos , Água/química
3.
Photodermatol Photoimmunol Photomed ; 29(5): 253-60, 2013 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-24001381

RESUMO

BACKGROUND: UV-blocking contact lenses were evaluated to determine if they could provide adequate ocular protection during narrowband UVB phototherapy treatment. Theoretical safe exposure durations for the crystalline lens, cornea and conjunctiva were determined. METHODS: A Cary 500 spectrophometer generated transmittance data for six UV-blocking and two non-UV-blocking contact lenses. An IL-1700 radiometer measured the lenses' radiation transmittance within the NB-UVB phototherapy unit. The lenses were exposed to a 1500-mJ/cm(2) dose of radiation from a 308-nm excimer laser to determine if the radiation would alter their protective properties. Theoretical safe exposure durations for eye structures were calculated using previous human and animal study data. RESULTS: All UV-blocking contact lenses showed less than 1E-7 W/cm(2) of radiation transmittance within the narrowband phototherapy unit. The excimer laser did not significantly alter the lenses' UV-blocking capabilities. The safe exposure durations for the cornea and crystalline lens were greater than 11 min with UV-blocking lenses, and that for the unprotected conjunctiva was approximately 11 s. CONCLUSION: Some UV-blocking contact lenses potentially provide sufficient ocular protection during narrowband UVB phototherapy treatment, as the crystalline lens and cornea are adequately protected should a patient open his or her eyes for a short time.


Assuntos
Lentes de Contato Hidrofílicas , Doenças Palpebrais/prevenção & controle , Transtornos de Fotossensibilidade/prevenção & controle , Raios Ultravioleta/efeitos adversos , Humanos
4.
Cornea ; 32(3): 365-9, 2013 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-22677638

RESUMO

PURPOSE: Toxic epidermal necrolysis (TEN) is a devastating form of Stevens-Johnson syndrome (SJS) with acute and chronic ocular complications. We present a novel aggressive combination strategy, termed "Triple-TEN", for the management of acute ocular TEN designed to minimize the risk of chronic, blinding sequelae. METHODS: Two patients with life-threatening TEN accompanied by severe ocular surface defects and fulminant symblephara formation underwent "Triple-TEN" management of their acute ocular disease under aseptic techniques in the critical care setting, after failed treatment with intensive topical therapy and surgical division of symblephara. The Triple-TEN protocol comprises (1) subconjunctival triamcinolone (Kenalog 20 mg) administered into each of the fornices to curb the local inflammatory response without compromising systemic immunity, (2) placement of amniotic membrane tissue mounted on a polycarbonate skirt (ProKera) over the corneal and limbal regions to facilitate reepithelialization of the ocular surface, and (3) insertion of a steeply curved acrylic scleral shell spacer (Technovent, SC21) to vault the lids away from the globe providing a barrier to symblephara formation. RESULTS: In both cases, ocular surface inflammation resolved within 4 weeks with no progression of conjunctival cicatrization or evidence of limbal epithelial stem cell failure at 1 year follow-up. There were no long-term complications of the Triple-TEN regimen. CONCLUSIONS: Aggressive treatment with the Triple-TEN protocol for acute ocular TEN resistant to first-line therapy, may help prevent long-term blinding sequelae.


Assuntos
Curativos Biológicos , Conjuntivite/terapia , Glucocorticoides/uso terapêutico , Próteses e Implantes , Síndrome de Stevens-Johnson/complicações , Síndrome de Stevens-Johnson/terapia , Triancinolona Acetonida/uso terapêutico , Resinas Acrílicas , Doença Aguda , Adolescente , Terapia Combinada , Conjuntivite/etiologia , Doenças Palpebrais/prevenção & controle , Feminino , Humanos , Pessoa de Meia-Idade , Cimento de Policarboxilato , Síndrome de Stevens-Johnson/etiologia
5.
Anat Rec A Discov Mol Cell Evol Biol ; 288(12): 1303-9, 2006 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-17075842

RESUMO

Valproic acid, a drug commonly used to treat seizures and other psychiatric disorders, causes neural tube defects (NTDs) in exposed fetuses at a rate 20 times higher than in the general population. Failure of the neural tube to close during development results in exencephaly or anencephaly, as well as spina bifida. In mice, nonspecific activation of the maternal immune system can reduce fetal abnormalities caused by diverse etiologies, including diabetes-induced NTDs. We hypothesized that nonspecific activation of the maternal immune system with interferon-gamma (IFN-gamma) and granulocyte-macrophage colony-stimulating factor (GM-CSF) could reduce valproic acid (VA)-induced defects as well. Female CD-1 mice were given immune stimulant prebreeding: either IFN-gamma or GM-CSF. Approximately half of the control and immune-stimulated pregnant females were then exposed to 500 mg/kg VA on the morning of gestational day 8. The incidence of developmental defects was determined on gestational day 17 from at least eight litters in each of the following treatment groups: control, VA only, IFN-gamma only, IFN-gamma+VA, GM-CSF only, and GM-CSF+VA. The incidence of NTDs was 18% in fetuses exposed to VA alone, compared to 3.7% and 2.9% in fetuses exposed to IFN-gamma+VA, or GM-CSF+VA respectively. Ocular defects were also significantly reduced from 28.0% in VA exposed groups to 9.8% in IFN-gamma+VA and 12.5% in GM-CSF+VA groups. The mechanisms by which maternal immune stimulation prevents birth defects remain unclear, but may involve maternal or fetal production of cytokines or growth factors which protect the fetus from the dysregulatory effects of teratogens.


Assuntos
Anormalidades Induzidas por Medicamentos/prevenção & controle , Adjuvantes Imunológicos/farmacologia , Anticonvulsivantes/toxicidade , Fator Estimulador de Colônias de Granulócitos e Macrófagos/farmacologia , Interferon gama/farmacologia , Defeitos do Tubo Neural/prevenção & controle , Ácido Valproico/toxicidade , Adjuvantes Imunológicos/uso terapêutico , Animais , Relação Dose-Resposta a Droga , Doenças Palpebrais/induzido quimicamente , Doenças Palpebrais/prevenção & controle , Pálpebras/anormalidades , Pálpebras/efeitos dos fármacos , Feminino , Morte Fetal , Reabsorção do Feto , Peso Fetal/efeitos dos fármacos , Idade Gestacional , Fator Estimulador de Colônias de Granulócitos e Macrófagos/uso terapêutico , Interferon gama/uso terapêutico , Exposição Materna , Troca Materno-Fetal , Camundongos , Defeitos do Tubo Neural/induzido quimicamente , Placenta/efeitos dos fármacos , Gravidez , Fatores de Tempo
6.
Br J Ophthalmol ; 89(10): 1282-8, 2005 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-16170117

RESUMO

BACKGROUND/AIM: Trachomatous trichiasis frequently returns following surgery. Several factors may promote recurrence: preoperative disease severity, surgeon ability, surgical procedure, healing responses, and infection. This study investigates whether enhanced control of infection, both of Chlamydia trachomatis and other bacteria, with azithromycin can improve surgical outcome in a trachoma control programme. METHODS: Individuals with trachomatous trichiasis were examined and operated. After surgery patients were randomised to the azithromycin or control group. The azithromycin group and children in their household were given a dose of azithromycin. Antibiotic treatment was repeated at 6 months. All patients were reassessed at 6 months and 12 months. Samples were collected for C trachomatis polymerase chain reaction and general microbiology at each examination. RESULTS: 451 patients were enrolled. 426 (94%) were reassessed at 1 year, of whom 176 (41.3%) had one or more lashes touching the eye and 84 (19.7%) had five or more lashes. There was no difference in trichiasis recurrence between the azithromycin and control group. Recurrent trichiasis was significantly associated with more severe preoperative trichiasis, bacterial infection, and severe conjunctival inflammation at 12 months. Significant variability in outcome was found between surgeons. Visual acuity and symptoms significantly improved following surgery. CONCLUSION: In this setting, with a low prevalence of active trachoma, azithromycin did not improve the outcome of trichiasis surgery conducted by a trachoma control programme. Audit of trichiasis surgery should be routine.


Assuntos
Antibacterianos/uso terapêutico , Azitromicina/uso terapêutico , Doenças Palpebrais/prevenção & controle , Doenças do Cabelo/prevenção & controle , Tracoma/prevenção & controle , Idoso , Bactérias/isolamento & purificação , Túnica Conjuntiva/microbiologia , Conjuntivite/complicações , Conjuntivite/microbiologia , Progressão da Doença , Infecções Oculares Bacterianas/complicações , Infecções Oculares Bacterianas/prevenção & controle , Pestanas , Doenças Palpebrais/microbiologia , Doenças Palpebrais/cirurgia , Feminino , Seguimentos , Gâmbia , Doenças do Cabelo/microbiologia , Doenças do Cabelo/cirurgia , Humanos , Masculino , Pessoa de Meia-Idade , Cuidados Pós-Operatórios/métodos , Prevenção Secundária , Índice de Gravidade de Doença , Tracoma/complicações , Tracoma/cirurgia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA